BioVaxys Provides Viral Vaccine Platform Program Update
- Written by ACN Newswire
Vancouver, BC, Dec 1, 2020 - (ACN Newswire) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels...
Read more: BioVaxys Provides Viral Vaccine Platform Program Update